Schlag Anne Katrin
Drug Science, London, United Kingdom.
King's College London, London, United Kingdom.
Med Cannabis Cannabinoids. 2020 Jan 15;3(1):76-83. doi: 10.1159/000505028. eCollection 2020 Aug.
This paper evaluates current regulatory regimes of medical cannabis using peer-reviewed and grey literature as well as personal communications. Despite the legalization of medical cannabis in the UK in November 2018, patients still lack access to the medicine, with fewer than 10 NHS prescriptions having been written to date. We look at six countries that have been at the forefront of prescribing medical cannabis, including case studies of the three largest medical cannabis markets in the EU: Germany, Italy, and the Netherlands. Canada, Israel and Australia add global examples. These countries have a more successful history of prescribing medical cannabis than the UK. Their legislations are outlined and numbers of medical cannabis prescriptions are provided to give an indication of how successful their regulatory regime has been in providing patient access. Evaluating countries' medical cannabis regulations allows us to offer implications for lessons to be learned for the development of a successful medical cannabis regime in the UK.
本文利用同行评审文献、灰色文献以及个人交流，对当前医用大麻的监管制度进行了评估。尽管2018年11月医用大麻在英国实现了合法化，但患者仍难以获得该药物，迄今为止，国民保健署（NHS）开出的处方不到10份。我们考察了六个在医用大麻处方方面处于前沿的国家，包括欧盟最大的三个医用大麻市场德国、意大利和荷兰的案例研究。加拿大、以色列和澳大利亚则提供了全球范围内的例子。这些国家在医用大麻处方方面的历史比英国更为成功。我们概述了它们的立法情况，并提供了医用大麻处方数量，以表明其监管制度在为患者提供获取渠道方面的成功程度。评估各国的医用大麻法规，有助于我们为英国建立成功的医用大麻制度提供可借鉴的经验教训。
